Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587651 | 0.90 | GSK3B (0.49) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4588003 | 0.89 | GSK3B (0.42) | GSK3BCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL4484075 | 0.87 | GSK3B (0.44) | GSK3BCYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4587236 | 0.84 | PIK3CD (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4587845 | 0.82 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4489193 | 0.82 | GSK3B (0.43) | GSK3BCYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL4588715 | 0.80 | GSK3B (0.44) | GSK3BCYP2D6CYP3A4 | |
| SCHEMBL4586356 | 0.80 | PIK3CD (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4589041 | 0.79 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4586932 | 0.79 | GSK3B (0.45) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318980-A1 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-12-25 | — | — | US | claimed |
| US-7429663-B2 | 7-(Pyrimidin-4-yl)-Imidazo[1,2-a]Pyrimidin-5(1H)-ones as GSK3β inhibitors | SANOFI-AVENTIS (FR) | 2008-09-30 | — | — | US | claimed |
| EP-1480981-B1 | 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | claimed |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | SANOFI (FR) | 2005-06-02 | — | — | US | claimed |
| EP-1340759-A1 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | claimed |
| US-20080318980-A1 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-12-25 | — | — | US | disclosed |
| US-7429663-B2 | 7-(Pyrimidin-4-yl)-Imidazo[1,2-a]Pyrimidin-5(1H)-ones as GSK3β inhibitors | SANOFI-AVENTIS (FR) | 2008-09-30 | — | — | US | disclosed |
| EP-1480981-B1 | 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | disclosed |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | SANOFI (FR) | 2005-06-02 | — | — | US | disclosed |
| EP-1340759-A1 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318980-A1 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS | GSK3B, GSK3A, PSEN1 | GSK3B 1/4885CYP1A2 1510/4885CYP2D6 2274/4885 |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | PSEN1, GSK3A, GSK3B | GSK3B 3/4885CYP1A2 402/4885CYP2D6 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.